Actively Recruiting
Phase 3 Randomized Study of Optune with Maintenance Temozolomide and Pembrolizumab versus Placebo in Newly Diagnosed Glioblastoma
Led by NovoCure GmbH · Updated on 2026-08-19
741
Participants Needed
102
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating a treatment for patients newly diagnosed with Glioblastoma GBM, a type of brain cancer. This multicenter, randomized, double-blind, placebo-controlled phase 3 study compares the combination of Optune Tumor Treating Fields at 200 kHz with maintenance Temozolomide chemotherapy plus pembrolizumab against Optune with maintenance Temozolomide plus placebo. The main goal is to evaluate overall survival over 24 months. Participants receive the Optune device delivering Tumor Treating Fields therapy at 200 kHz alongside maintenance Temozolomide chemotherapy given daily for 5 days in 28-day cycles. Additionally, participants receive either pembrolizumab or a placebo intravenous infusion of 200 mg every three weeks, for up to 35 cycles. Prior to enrollment, participants must have completed maximal surgical removal of the tumor, standard chemoradiotherapy, and be suitable for this combined treatment. Throughout the study, participants are monitored for survival and progression-free survival at 24 months, with assessments including clinical evaluations and treatment adherence. Safety and effectiveness are carefully observed during and after treatment. The study is expected to run until April 2029, offering long-term follow-up to understand treatment outcomes in this patient population.
CONDITIONS
Brief Title
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Research Team
U
Uz Stammberger
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here